These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2183 related items for PubMed ID: 18559522

  • 1. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Wedge SR, Jürgensmeier JM, Alitalo K.
    Cancer Res; 2008 Jun 15; 68(12):4754-62. PubMed ID: 18559522
    [Abstract] [Full Text] [Related]

  • 2. Molecular control of lymphatic metastasis.
    Achen MG, Stacker SA.
    Ann N Y Acad Sci; 2008 Jun 15; 1131():225-34. PubMed ID: 18519975
    [Abstract] [Full Text] [Related]

  • 3. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang S, Wang W, Zhang J, Zhang Y.
    Eur J Cancer; 2011 Oct 15; 47(15):2353-63. PubMed ID: 21680174
    [Abstract] [Full Text] [Related]

  • 4. Differential expression of VEGF ligands and receptors in prostate cancer.
    Woollard DJ, Opeskin K, Coso S, Wu D, Baldwin ME, Williams ED.
    Prostate; 2013 May 15; 73(6):563-72. PubMed ID: 23038639
    [Abstract] [Full Text] [Related]

  • 5. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.
    Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholová I, Kauppinen RA, Achen MG, Stacker SA, Alitalo K, Ylä-Herttuala S.
    Circ Res; 2003 May 30; 92(10):1098-106. PubMed ID: 12714562
    [Abstract] [Full Text] [Related]

  • 6. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
    Kodera Y, Katanasaka Y, Kitamura Y, Tsuda H, Nishio K, Tamura T, Koizumi F.
    Breast Cancer Res; 2011 Jun 21; 13(3):R66. PubMed ID: 21693010
    [Abstract] [Full Text] [Related]

  • 7. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
    Davydova N, Harris NC, Roufail S, Paquet-Fifield S, Ishaq M, Streltsov VA, Williams SP, Karnezis T, Stacker SA, Achen MG.
    J Biol Chem; 2016 Dec 30; 291(53):27265-27278. PubMed ID: 27852824
    [Abstract] [Full Text] [Related]

  • 8. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
    Kaushal V, Mukunyadzi P, Dennis RA, Siegel ER, Johnson DE, Kohli M.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):584-93. PubMed ID: 15701844
    [Abstract] [Full Text] [Related]

  • 9. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
    Chung TW, Kim SJ, Choi HJ, Kim KJ, Kim MJ, Kim SH, Lee HJ, Ko JH, Lee YC, Suzuki A, Kim CH.
    Glycobiology; 2009 Mar 15; 19(3):229-39. PubMed ID: 18974200
    [Abstract] [Full Text] [Related]

  • 10. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms.
    Kodama M, Kitadai Y, Tanaka M, Kuwai T, Tanaka S, Oue N, Yasui W, Chayama K.
    Clin Cancer Res; 2008 Nov 15; 14(22):7205-14. PubMed ID: 19010837
    [Abstract] [Full Text] [Related]

  • 11. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW, Lien JC, Kuo SC, Huang TF.
    Carcinogenesis; 2012 May 15; 33(5):1022-30. PubMed ID: 22436611
    [Abstract] [Full Text] [Related]

  • 12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 13. Extracellular matrix regulates endothelial functions through interaction of VEGFR-3 and integrin alpha5beta1.
    Zhang X, Groopman JE, Wang JF.
    J Cell Physiol; 2005 Jan 15; 202(1):205-14. PubMed ID: 15389531
    [Abstract] [Full Text] [Related]

  • 14. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin.
    Liu ZY, Qiu HO, Yuan XJ, Ni YY, Sun JJ, Jing W, Fan YZ.
    Int J Oncol; 2012 Nov 15; 41(5):1762-72. PubMed ID: 22922710
    [Abstract] [Full Text] [Related]

  • 15. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues.
    Lohela M, Heloterä H, Haiko P, Dumont DJ, Alitalo K.
    Am J Pathol; 2008 Dec 15; 173(6):1891-901. PubMed ID: 18988807
    [Abstract] [Full Text] [Related]

  • 16. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
    Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ.
    Cancer Res; 2005 May 15; 65(10):4389-400. PubMed ID: 15899831
    [Abstract] [Full Text] [Related]

  • 17. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
    Chen HM, Tsai CH, Hung WC.
    Oncotarget; 2015 Jun 20; 6(17):14940-52. PubMed ID: 25909285
    [Abstract] [Full Text] [Related]

  • 18. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.
    Von Marschall Z, Scholz A, Stacker SA, Achen MG, Jackson DG, Alves F, Schirner M, Haberey M, Thierauch KH, Wiedenmann B, Rosewicz S.
    Int J Oncol; 2005 Sep 20; 27(3):669-79. PubMed ID: 16077915
    [Abstract] [Full Text] [Related]

  • 19. Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands.
    Chung ES, Chauhan SK, Jin Y, Nakao S, Hafezi-Moghadam A, van Rooijen N, Zhang Q, Chen L, Dana R.
    Am J Pathol; 2009 Nov 20; 175(5):1984-92. PubMed ID: 19808642
    [Abstract] [Full Text] [Related]

  • 20. VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study.
    Visuri MT, Honkonen KM, Hartiala P, Tervala TV, Halonen PJ, Junkkari H, Knuutinen N, Ylä-Herttuala S, Alitalo KK, Saarikko AM.
    Angiogenesis; 2015 Jul 20; 18(3):313-26. PubMed ID: 26018927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 110.